Summary

PT Bio Farma has established a pharmaceutical holding company with PT Kimia Farma Tbk and Indofarma Tbk as members. The holding company was formed to increase the production capacity of the Indonesian pharmaceutical industry. The Director of Bio Farma, Honesti Basyir, said that the high cost of health products in Indonesia is due to inefficient production. The holding company will increase efficiency through synergy among its members. The holding company will also reduce the import of health products by increasing production capacity. Bio Farma will remain focused on its core business while Kimia Farma will strengthen the supply chain and Indofarma will increase competitiveness in the pharmaceutical and medical device industry.
The pharmaceutical holding company was established on January 31 with PT Bio Farma as the parent company and PT Kimia Farma Tbk and Indofarma Tbk as members. The holding company was formed to increase the production capacity of the Indonesian pharmaceutical industry. The high cost of health products in Indonesia is due to inefficient production. The holding company will increase efficiency through synergy among its members. The holding company will also reduce the import of health products by increasing production capacity.
Bio Farma will remain focused on its core business while Kimia Farma will strengthen the supply chain and Indofarma will increase competitiveness in the pharmaceutical and medical device industry. The holding company will make the production process more efficient by integrating the fragmented pharmaceutical manufacturing business. The holding company will support the government's program to reduce the import of health products and increase the accessibility and affordability of health products in Indonesia.